Expand IBRX Menu
IBRX MENU

IBRX Latest Press Releases

-- December 16, 2025 --

Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX) AB Digital Inc 3:16 PM
ANKTIVA with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer Business Wire 9:00 AM

-- December 12, 2025 --

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe Business Wire 6:10 AM

-- November 13, 2025 --

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations Business Wire 9:00 AM

-- November 4, 2025 --

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 Business Wire 10:12 PM

-- September 8, 2025 --

ImmunityBio's ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy Business Wire 8:30 AM

-- August 26, 2025 --

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA, NK Cell Therapy Plus Optune Gio Device Business Wire 8:30 AM

-- August 19, 2025 --

ImmunityBio Announces Phase 2 Study of ANKTIVA in Patients with Long COVID Business Wire 8:30 AM

-- August 13, 2025 --

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy Business Wire 8:30 AM

-- August 11, 2025 --

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA to Bladder Cancer Patients Business Wire 8:30 AM

-- August 5, 2025 --

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code Business Wire 7:00 AM

-- July 25, 2025 --

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors Business Wire 6:03 AM
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates Business Wire 6:00 AM
Market Data Delayed 15 Minutes